Ischaemic conditioning and targeting reperfusion injury: a 30 year voyage of discovery by Hausenloy DJ et al.
MEETING REPORT
Ischaemic conditioning and targeting reperfusion injury:
a 30 year voyage of discovery
Derek J. Hausenloy1,2,3,4 • Jose A. Barrabes5 • Hans Erik Bøtker6 • Sean M. Davidson1 • Fabio Di Lisa7 •
James Downey8 • Thomas Engstrom9 • Pe´ter Ferdinandy10,11 • Hector A. Carbrera-Fuentes3,4,12,13 •
Gerd Heusch14 • Borja Ibanez15,16 • Efstathios K. Iliodromitis17 • Javier Inserte5 • Robert Jennings18 •
Neena Kalia19 • Rajesh Kharbanda20 • Sandrine Lecour21 • Michael Marber22 • Tetsuji Miura23 •
Michel Ovize24,25 • Miguel A. Perez-Pinzon26,27,28 • Hans Michael Piper29 • Karin Przyklenk30 •
Michael Rahbek Schmidt3 • Andrew Redington31 • Marisol Ruiz-Meana5 • Gemma Vilahur32 •
Jakob Vinten-Johansen33 • Derek M. Yellon1,2 • David Garcia-Dorado5
Received: 2 October 2016 / Accepted: 11 October 2016 / Published online: 20 October 2016
 The Author(s) 2016. This article is published with open access at Springerlink.com
Abstract To commemorate the auspicious occasion of the
30th anniversary of IPC, leading pioneers in the field of
cardioprotection gathered in Barcelona in May 2016 to
review and discuss the history of IPC, its evolution to IPost
and RIC, myocardial reperfusion injury as a therapeutic
target, and future targets and strategies for cardioprotec-
tion. This article provides an overview of the major topics
discussed at this special meeting and underscores the huge
importance and impact, the discovery of IPC has made in
the field of cardiovascular research.
Keywords Ischaemic conditioning  Myocardial
reperfusion injury  Cardioprotection  RISK and SAFE
pathway  Mitochondria
& Derek J. Hausenloy
derek.hausenloy@duke-nus.edu.sg
& David Garcia-Dorado
dgdorado@vhebron.net
1 The Hatter Cardiovascular Institute, University College
London, London, UK
2 The National Institute of Health Research University
College London Hospitals Biomedical Research Centre,
London, UK
3 Cardiovascular and Metabolic Disorders Program, Duke-
National University of Singapore, 8 College Road,
Singapore 169857, Singapore
4 National Heart Research Institute Singapore, National Heart
Centre Singapore, Singapore, Singapore
5 Department of Cardiology, Vall d’Hebron University
Hospital and Research Institute, Universitat Auto`noma,
Barcelona, Spain
6 Department of Cardiology, Aarhus University Hospital
Skejby, 8200 Aarhus N, Denmark
7 Department of Biomedical Sciences and CNR Institute of
Neurosciences, University of Padova, Padua, Italy
8 Department of Physiology and Cell Biology, College of
Medicine, University of South Alabama, Mobile, AL, USA
9 Department of Cardiology, Rigshospitalet, Copenhagen
University Hospital, Copenhagen, Denmark
10 Department of Pharmacology and Pharmacotherapy,
Semmelweis University, Budapest, Hungary
11 Pharmahungary Group, Szeged, Hungary
12 Institute for Biochemistry, Medical Faculty Justus-Liebig-
University, Giessen, Germany
13 Department of Microbiology, Kazan Federal University,
Kazan, Russian Federation
14 Institute for Pathophysiology, West-German Heart and
Vascular Center, University of Essen Medical School, Essen,
Germany
15 Centro Nacional de Investigaciones Cardiovasculares Carlos
III (CNIC), Madrid, Spain
16 IIS-Fundacio´n Jime´nez Dı´az Hospital, Madrid, Spain
17 2nd University Department of Cardiology, National and
Kapodistrian University of Athens, Athens, Greece
18 Duke University, Durham, NC, USA
19 Institute of Cardiovascular Sciences, University of
Birmingham, Birmingham, UK
20 Oxford Heart Centre, The John Radcliffe Hospital, Oxford
University Hospitals, Oxford, UK
123
Basic Res Cardiol (2016) 111:70
DOI 10.1007/s00395-016-0588-8
Introduction
The year 2016 marks the 30th anniversary since Murry,
Jennings and Reimer first discovered the phenomenon of
ischaemic preconditioning (IPC) [180]. The seminal dis-
covery in 1986, that brief episodes of ischaemia and
reperfusion could dramatically reduce myocardial infarct
(MI) size, gave rise to the field of cardioprotection, and has
resulted in over 10,000 publications in the research litera-
ture. Over the last 30 years enormous efforts have been
made to understand the mechanisms underlying IPC and
have provided huge insights into the mechanisms of car-
diomyocyte death during acute ischaemia/reperfusion
injury (IRI), and the complex signalling pathways under-
lying cytoprotection within the cardiomyocyte and beyond.
In addition, the last 30 years have witnessed enormous
efforts to translate this endogenous cardioprotective strat-
egy into the clinical setting for patient benefit. In this
regard, the evolution of IPC to an intervention which could
be applied at the time of reperfusion [ischaemic postcon-
ditioning (IPost)] [276] and to a remote organ or tissue
[remote ischaemic conditioning (RIC)] [200] has facilitated
the translation of IPC into the clinical setting.
To commemorate the auspicious occasion of the 30th
anniversary of IPC, leading pioneers in the field of car-
dioprotection gathered in Barcelona in May 2016 to review
and discuss the history of IPC (Fig. 1), its evolution to
IPost and RIC, myocardial reperfusion injury as a thera-
peutic target, and future targets and strategies for cardio-
protection. This article provides an overview of the major
topics discussed at this special meeting and underscores the
huge importance and impact, the discovery of IPC has
made in the field of cardiovascular research.
Ischaemic preconditioning
In IPC, several minutes of acute coronary occlusion followed
by reperfusion delay the onset of MI from a subsequent
period of prolonged lethal ischaemia and reperfusion. The
description of IPC 30 years ago in 1986 by Murry et al. [180]
was a landmark discovery. It proved once and for all that the
final size of a MI was not only a function of the area-at-risk
(AAR), ischaemic time and collateral flow, but could indeed
be reduced, as had been originally proposed by Braunwald
and colleagues years before [165]. The Jennings laboratory
was pursuing the observation that a brief ischaemic episode
slowed the rate of ATP consumption when the heart was
subjected to subsequent episodes of ischaemia. Since virtu-
ally no ATP is present in dead cardiomyocytes, they
hypothesised that delaying ATP depletion would attenuate
the development of cardiomyocyte death [181].
Considering the huge number of papers eventually
published on IPC since 1986, it is amazing that it took
4 years before the first confirmatory paper by another
laboratory appeared on the subject [149]. However, after
that virtually everyone who tried to replicate IPC was able
to observe protection that lasted for several hours [258]. In
1991, Liu et al. [153] showed that the preconditioned state
resulted from protective signal transduction. Infusing ade-
nosine or an adenosine A1 receptor-selective agonist into
the coronary arteries for 5 min prior to occluding a coro-
nary branch put the heart into a protected state identical to
IPC. Conversely, an adenosine receptor antagonist com-
pletely blocked the IPC protection but had no effect on a
non-IPC heart. A1 receptors are Gi-coupled and act to slow
the heart rate as opposed to the Gs-coupled adenosine A2
receptors which act to dilate the coronary arteries. In fact it
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was shown that many of the Gi-coupled receptors in the
heart can mimic IPC [40]. A brief coronary occlusion has
been found to release ligands for only four of these
receptors: adenosine, bradykinin, opioid, and sphingosine.
These four receptors act in an additive fashion. Blocking a
single receptor subtype only raises the ischaemic threshold
for protection rather than abolishing the IPC response.
Subsequent studies quickly showed that protein kinase C
[155] and ATP-sensitive potassium channels (KATP) [5],
which later turned out to be in the mitochondria [154] and
could be stimulated by diazoxide (pharmacological pre-
conditioning), were also in the IPC signalling pathway.
The overall signalling pathway is still not completely
understood but extensive research in many laboratories has
revealed much of it (Fig. 2) [29, 74, 101, 273]. In 2002,
Yellon’s group [86, 94, 218] proposed the Reperfusion
Injury Salvage Kinase or RISK Pathway to describe a group
of pro-survival kinases that must be activated at the time of
reperfusion for IPC to protect against MI. Since protection
could be aborted by blocking the RISK pathway at reper-
fusion, IPC must, therefore, protect against a reperfusion
injury. They also went on to demonstrate the importance of
this pathway in all forms of the conditioning process, i.e.
pre-, post-, remote and pharmacological conditioning [90]. It
now appears that much of the cell death in the heart is due to
the formation of permeability transition pores (PTPs) in the
mitochondrial membranes in the first minutes of reperfusion,
and IPC through the RISK signalling protects by suppressing
these PTPs [97, 103]. Lecour et al. [146] subsequently
identified the Salvage Activating Factor Enhancement
(SAFE) pathway which is activated in parallel to the RISK
pathway and appears to play a more important role in larger
mammals [78, 108, 227, 229].
The key to understanding IPC is to appreciate why the
brief period of reperfusion after the preconditioning
ischaemia is so important. The Gi receptor activation leads
to opening of mitochondrial KATP channels during
ischaemia and potassium entry into the mitochondria.
When oxygen is reintroduced during the reperfusion phase
of the IPC protocol, elevated mitochondrial potassium
stimulates the mitochondria to produce reactive oxygen
species (ROS). These ROS cause redox signalling which
ultimately results in PKC activation and completion of the
IPC signalling pathway [52]. In a non-conditioned heart
this pathway is blocked at the redox signalling step during
the prolonged ischaemic period as potassium has entered
the mitochondria but there is no oxygen available. If the
heart is reperfused after a prolonged ischaemic period PTPs
will always open before redox signalling can activate the
downstream pathway to inhibit them [37]. A large series of
recent studies have demonstrated that connexin 43, the
protein forming gap junction channels between cardiomy-
ocytes, is also located at the inner mitochondrial membrane
[15], where it can form hemi-channels that allow the pas-
sage of potassium [175], and that its absence at that loca-
tion prevents ROS generation during the IPC stimulus [98],
and abolishes cardioprotection [205]. There is recent evi-
dence that IPC can protect mitochondria against respiratory
inhibition induced by prolonged IRI independently of
cytosolic signalling [215].
Although IPC is clearly protective, the need for its
application before ischaemia makes it impractical for
Fig. 1 Faculty photo at the 30 year anniversary celebration of IPC in
Barcelona May 2016: ‘‘Ischaemic conditioning and targeting reper-
fusion injury: a 30 year voyage of discovery’’. Back row, left to right
Michael Rahbek Schmidt, Peter Ferdinandy, Hans Erik Bøtker,
Rajesh Kharbanda, Michael Marber, Pasquale Pagliaro, Thomas
Engstrom, Karin Przyklenk, Tetsuji Miura, Hector A. Carbrera-
Fuentes, Sandine Lecour, Derek Hausenloy, Derek Yellon, Borja
Ibanez, Rainer Schulz, Gerd Heusch, Hans Michael Piper, Efstathios
Iliodromitis, Miguel A Perez-Pinzon, Gemma Vilahur, Marisol Ruiz-
Meana. Front row, left to right David Garcia-Dorado, Javier Inserte,
Jose Barrabes, Robert Jennings, Jakob Vinten-Johansen, Andrew
Redington, Michel Ovize, Fabio Di Lisa, James Downey
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treating acute myocardial infarction (AMI). However, if the
protective pathway can be rapidly activated by a drug
administered at reperfusion (known as ‘‘pharmacological
postconditioning’’) then this can ‘‘win the race’’ and protect
the heart against reperfusion injury. Because much of con-
ditioning’s signal transduction pathway is now known [101],
it has been possible to identify agents effective at inducing
pharmacological postconditioning. Figure 2 shows a tenta-
tive map of the signalling pathways underlying IPC, and
some known interventions that, at least in animal models,
reportedly put the heart into a conditioned state.
Second window of protection
The second window of protection (SWOP) describes the
increased resistance to myocardial injury that re-appears
12–24 h after the short durations of ischaemia/reperfusion
that trigger classic or early preconditioning. This phe-
nomenon was first described in 1993 by independent
research groups based in London [164] and Osaka [140].
Yellon’s group in London had been interested in the
cardiac protection that followed whole body heart stress—
this was known to be associated with the induction of stress
proteins and catalase within the myocardium [44]. However,
whole body heat stress was associated with a multitude of
changes both within and outside the heart. Using an exper-
imental method that involved a support animal providing
oxygenated blood to perfuse a donor animal’s isolated heart,
evidence had been obtained that whilst whole body heat
stress protected the heart, it also triggered extra-cardiac
adaptations that aggravated myocardial injury [252]. This
observation provided the impetus to find a way of spatially
restricting the stress response to the heart, thereby avoiding
the deleterious systemic adaptations associated with whole
body heart stress. In 1991, Knowlton had observed cardiac
stress protein induction beginning 6–8 h after short episodes
of myocardial ischaemia [136]. Based on this observation, it
was reasoned that sublethal myocardial ischaemia would
induce stress proteins without causing the detrimental sys-
temic response associated with whole body heat stress. It
was on this basis that Marber et al. designed and performed
the experiments that laid the foundation for the SWOP
[164].
Following the original observations by Marber [164]
and Kuzuya [139], there followed a number of basic sci-
ence studies that indicated the SWOP had a duration of
72–96 h, and whilst the magnitude of protection may be
less robust than that of the first window of protection, there
were likely to be important clinical correlates [272].
Fig. 2 A proposed map of some of the major signalling pathways
involved in ischaemic pre- and postconditioning. The pink coloured
boxes indicate pharmacological interventions that have been reported
to reduce MI size when administered just prior to reperfusion. They
are positioned near their proposed site of action. Figure modified from
that appearing in [38]
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Studies in patients have broadly fallen into two groups;
observational studies, where symptoms and circumstance
are related to outcome after spontaneous plaque rupture
(type I MI) and interventional studies using controlled,
iatrogenic myocardial ischaemia. In the observational
studies, it was found that patients who experience repeated
episodes of pre-infarction angina more than 24 h before the
index event, may develop smaller final MI size than those
without pre-infarction angina [102, 184]. Interpretation of
these studies is complicated by the variation of each
ischaemic episode in terms of its duration, intensity and
exact timing before spontaneous coronary artery occlusion.
Furthermore, most patients have co-morbidities and med-
ications that have been shown to both facilitate and prevent
the manifestation of protection. These uncontrollable
variables may explain the discrepancies that appear in the
literature regarding the benefit of pre-infarction angina.
Consequently, the benefit of the SWOP is more easily
demonstrated in interventional studies that use exercise
treadmill tests, isotope scintigraphy or coronary angio-
plasty to cause and document myocardial ischaemia
[14, 121, 143, 190].
In conclusion, the SWOP is clinically apparent under
pre-specified controlled conditions but is impossible to
identify with certainty in observational retrospective stud-
ies relevant to everyday clinical practice. Furthermore, the
systematic changes in primary percutaneous coronary
intervention (PPCI) services ensure early intervention with
the surety of reperfusion further secured by advances in
antiplatelet drugs and interventional devices [262]. On this
background it is very difficult to demonstrate sufficient
room for novel cardiac protection [28, 76, 99, 110, 262].
Furthermore, any benefit of SWOP may be subsumed by
ischaemic pre- and/or post-conditioning. Nonetheless, one
aspect of SWOP which may yet prove important is its
potential to reveal novel protective proteins that may form
the basis of future therapies.
Remote ischaemic conditioning
Remote ischaemic conditioning is the intriguing phe-
nomenon, first reported by Przyklenk, Whittaker and col-
leagues [200, 260], that brief periods of ischaemia applied
in a distant tissue can render the heart resistant to IRI and
reduce MI size. Although first viewed as a specious finding
[201], the concept of RIC-induced cardioprotection has,
during the past two decades, been corroborated in multiple,
diverse models (reviewed in [29, 93, 104, 193, 226]). A
recent meta-analysis of experimental studies in RIC found
that RIPC reduced MI size as a percentage of AAR by
22.8 %, when compared to untreated controls, and RIPerC/
RIPostC reduced MI size by 22.2 % [26]. Moreover, two
priorities have emerged: (1) identification of the mecha-
nisms responsible for the infarct-sparing effect of RIC; and
(2) translation of RIC to patient cohorts.
The molecular mechanisms contributing to RIC are,
without question, complex and remain incompletely
resolved [30–32, 93, 101, 104, 193, 226]. In brief, the
current hypothesis is that RIC induces a neuro-humoral
response which, in turn, induces a cascade of downstream
effects. Evidence for a neural component of RIC comes
from early observations that pretreatment of animals with
the ganglion blocker hexamethonium abolishes the car-
dioprotective effect of transient mesenteric ischaemia [68],
and subsequent studies showing that transection of the
ipsilateral femoral nerve [152, 235], or bilateral cervical
vagotomy [50], abolishes cardioprotection by RIC induced
by limb ischaemia. Conversely, direct stimulation of the
femoral nerve [204] or sensory nerves [169] within the
limb have been shown to induce cardioprotection. How-
ever, there are also controversial data on neuronal
involvement in RIC, as hexamethonium [257] or nerve
transection [203] did not abrogate cardioprotection. The
consequence of any neural stimulus, whether local to the
limb [221] or of the cardiac ganglia [194], is the release of
dialysable cardioprotective substances into the blood [129].
These include the chemokine SDF-1a [47], Ribonuclease-1
[30], leukotrienes [224], and microRNA 144 [150]. The
exact mechanism by which any of these putative effectors
are released, and their relative importance remains to be
fully understood. Yet, the ultimate effect at the car-
diomyocyte level is to induce a protective kinase response
[151, 227], and modification of PTP opening [247], similar
to that observed with local preconditioning and postcon-
ditioning. Unlike local preconditioning and postcondition-
ing, RIC appears to have additional pleiotropic effects that
modify pathways involved in the acute and chronic
responses to IRI and may contribute to its benefits,
including improved vascular endothelial function [158],
decreased platelet aggregation [10, 191], and a significant
anti-inflammatory effect manifest early by decreased neu-
trophil adhesion [220], and later by reduced inflammatory
cell infiltration, reduced local inflammation [30] and
reduced remodelling in the weeks after experimental MI
[256].
In the clinical setting, remote ischaemic preconditioning
(RIPC) has been administered prior to IRI as three or four
cycles of 5 min ischaemia followed by 5 min reperfusion
of the upper, or less frequently, lower limb in cardiac and
vascular surgery, and elective and emergency angioplasty.
The majority of studies in coronary artery bypass graft
(CABG) surgery patients have shown reduction of post-
operative cardiac biomarker release [2, 33, 35, 84,
138, 239, 240, 250] while others did not
[69, 131, 159, 167, 202, 275]. One randomized study of
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329 CABG patients demonstrated simultaneous reduction
of troponin I release and reduction of all-cause mortality up
to 4 years following the operation [91]. In contrast, a
randomised study of 1280 patients undergoing off-pump
coronary artery bypass graft surgery showed no effect of
RIPC before and after the surgery on a comprehensive
composite endpoint [113]. Two more recent studies, the
ERRICA and the RIPHeart studies, also failed to demon-
strate any beneficial effect on major adverse cardiac and
cerebral events (MACCE) after 12 months and event free
survival after 3 months, respectively [77, 171]. Studies that
failed to demonstrate a beneficial effect of RIPC used
propofol as an anaesthetic regimen. Similar experiences
have been obtained in major non-cardiac surgery [3, 254].
A specific effect of propofol that interacts with neuronal
transfer of the protective RIPC signal may interfere with
the inherent cardioprotective effect of propofol and further
protection by RC [137, 138].
Invasive coronary procedures circumvent any influence
from anaesthetics. In this setting, RIPC attenuated the
release of ischaemic markers in the majority of studies
including patients undergoing elective percutaneous coro-
nary intervention (PCI) [114, 162, 198, 265, 277], and
translated into a prognostic benefit in terms of MACCE at
follow-up period of up to 6 years [49]. Whilst RIPC can be
used in predictable ischaemia, another temporal variant is
necessary in unpredictable ischaemia such as ST-segment
elevation myocardial infarction (STEMI). Remote
ischaemic perconditioning (RIPerC) [217], in which the
RIC intervention is applied during evolving MI prior to
PPCI, has consistently yielded cardioprotection in proof-
of-concept studies using a variety of outcome measures
including myocardial salvage, ST-segment resolution and
biomarker release (Table 1) [25, 42, 54, 179, 199,
205, 259, 271]. The reduction of MI size translated into a
reduction of MACCE [230] and was cost-effective [231]
over a 4-year period following the index infarct. This study
included 333 patients and was not powered for clinical
outcomes. The ongoing CONDI-2/ERIC-PPCI study
including 4300 patients will determine the clinical benefit
of RIPerC as an adjunct to PPCI in patients with STEMI
[79].
Ischaemic postconditioning
Emergence of the concept of ischaemic postconditioning
(IPost) was based on four points: (a) myocardial reperfu-
sion injury was not a laboratory curiosity but an patho-
physiological entity that exacerbated tissue injury (whether
de novo or extending pre-existing injury) after onset of
reflow; (b) lethal myocardial reperfusion injury was initi-
ated quickly after the onset of reperfusion; (c) tissue des-
tined to die in the path of the reperfusion injury ‘‘wave
front’’ after onset of reflow could be salvaged; (d) reper-
fusion injury pathology could be avoided or prevented by
Table 1 Proof-of-concept studies of remote ischaemic conditioning in STEMI
Study No of patients
(control/RIC)
RIC regimen Endpoint Outcome
Bøtker et al.
[25]
69/73 Upper limb
4 cycles I/R (5/5 min)
Salvage index
(SPECT)
20 % increase in salvage index
Munk et al.
[179]
110/108 Upper limb
4 cycles I/R (5/5 min)
LVEF at 30 days 5 % increase in LVEF in anterior infarcts
Rentoukas
et al. [205]
30/33 Upper limb
3 cycles I/R (5/5 min)
ST-segment
resolution
20 % increase in proportion of patients achieving
full ST-segment resolution
Crimi et al.
[42]
50/50 Lower limb
3 cycles I/R (5/5 min)
CK-MB (AUC 72 h
after PCI)
20 % reduction of CK-MB release
Prunier et al.
[199]
17/18 Upper limb
4 cycles I/R (5/5 min)
CK-MB (AUC 72 h
after PCI)
31 % reduction of CK-MB release
Yellon et al.
[271]
260/260 Upper limb
4 cycles I/R (5/5 min)
TnT (AUC 24 h
after PCI)
17 % reduction of TnT release
White et al.
[259]
40/43 Upper limb
4 cycles I/R (5/5 min)
Cardiac MRI 27 % reduction of MI size
Eitel et al. [54] 232/232/232 Upper limb
3 cycles I/R (5/5 min) ?
local IPost)
Salvage index
(cardiac MRI)
23 % increase in salvage index
AUC area under curve, CK-MB creatine kinase-myocardial band, LVEF left ventricular ejection fraction, MRI magnetic resonance imaging, PCI
percutaneous coronary intervention, SPECT single photon emission computerised tomography, Tn troponin
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altering how the ischaemic tissue was reperfused. The latter
point was expanded to include modifying the conditions
and composition of the reperfusate, including the inclusion
of drugs during early reperfusion. Despite considerable
controversy over the very existence and clinical importance
of myocardial reperfusion injury, there is now compelling
evidence that reperfusion contributes to the extent of
transient as well as permanent (lethal) post-ischaemic
injury to the myocardium [27, 65, 73, 251, 274], and that
this injury was initiated within moments after onset of
reflow [246]. Early reports of the protective effects of
gradual or gentle reperfusion (modified conditions of
reperfusion) in the early moments of reperfusion
[22, 115, 216] did not capture the attention of the scientific
or clinical communities. Although initial trials on IPost
were performed in 1992, results were negative due to
(a) excessively long durations of the reperfusion-re-occlu-
sion cycles (5 min emulating preconditioning cycles), and
(b) a single cycle rather than multiple cycles; studies
resumed eight years later using shorter cycle durations in a
large animal model which successfully reduced MI size,
coronary artery endothelial dysfunction, oedema in the
AAR, and apoptosis [276].
Studies confirming and extending the original resultswere
published quickly by independent laboratories [63, 245, 270]
as well as by Vinten-Johansen’s laboratory [71, 135]. Kin
et al. [135] showed that the cardioprotective effects of IPost
were not observed if the manoeuver was delayed by 60 s,
confirming that a IPost window opened in the first few
minutes of reperfusion which was critical to protection. This
IPost window was confirmed by Yang et al. [270] and
implied that reperfusion injury interventions should be
implemented immediately at or before the onset of reperfu-
sion. There is scant evidence that delayed postconditioning is
effective in reducing post-ischaemic injury [209].
IPost has been shown to reduce abnormal alterations in a
multitude of end points associated with post-ischaemic
injury. These include reduction of (1) MI size and possibly
the no-reflow area, (2) apoptosis, (3) interstitial and intra-
cellular oedema, (4) early post-ischaemic arrhythmias, (5)
the pro-inflammatory response to reperfusion, (6) explosive
(injurious) ROS generation by multiple cell types, and (7)
the incidence of heart failure. Whether IPost attenuates
transient (stunning) or permanent contractile dysfunction
globally or regionally is controversial. In addition, the
cardioprotection of IPost may be lost in the presence of
comorbidities (diabetes, hypertension, and hypercholes-
terolemia) or co-medications (such as P2Y12 inhibitors), in
older individuals [19, 56, 225]. Although these data may
imply limited efficacy in patients that present with isolated
or the constellation of comorbidities in the metabolic
syndrome, it must be said that efficacy has been shown in
patients that present for PCI with these demographics
[192].
The mechanisms by which these physiological respon-
ses to reperfusion are attenuated include (1) inhibiting PTP
opening [4, 85, 103], (2) delaying rapid myocardial re-
alkalinisation that, in part, contributes to PTP opening [39],
(3) reducing intracellular and intra-mitochondrial calcium
accumulation [117], (4) reduced oxidative damage of
eNOS and preserved cGMP signalling [125], (5) attenuat-
ing endothelial dysfunction (expression of adhesion mole-
cules [276], production of NO, and other vasoactive and
cardioprotective autacoids such as adenosine) that other-
wise trigger the vascular inflammatory response to reper-
fusion injury, and (6) reducing pro-inflammatory cell
activation and expression of cytokines in blood that con-
tribute to the inflammatory response to reperfusion injury
[31, 32]. A year after its introduction, Tsang et al. [245]
reported that IPost activated the reperfusion injury salvage
kinase (RISK) pathway pro-survival kinases PI3K-Akt and
downstream targets eNOS and p70S6K (see later section).
Unlike preconditioning whose clinical application is
limited by the unpredictability of AMI, IPost immediately
caught the attention of interventional cardiologists. In
2005, Staat et al. [234] reported that four episodes of 1-min
inflation–deflation cycles of the angioplasty balloon per-
formed immediately after coronary artery re-opening were
able to significantly reduce MI size in STEMI patients.
This was the first report demonstrating that reperfusion
injury exists in man, is of pathophysiological importance,
and can be attenuated by a timely intervention. Most
[133, 238, 241], but not all [132], clinical studies in
patients with these conditions undergoing PCI or cardiac
surgery have shown positive outcomes with IPost (re-
viewed in Heusch [99, 101, 110]). Reasons for such dis-
crepancy are unclear but might include a different use of
thrombus aspiration, direct stenting, in-stent balloon infla-
tion–deflation for inducing IPost, as well as the con-
founding role of new adjunct therapies like P2Y12
inhibitors. The recent phase 3 DANAMI-3 IPOST study
(NCT01435408) [111] reported that 4 cycles of 30 s IPost
failed to improve clinical outcomes in STEMI patients, but
this study used a sub-optimal IPost algorithm and was
probably underpowered. Additional studies are awaited to
clarify whether or not MI size reduction observed in phase
2 IPost trials can actually provide any clinical benefit to
STEMI patients.
Whether IPost is cardioprotective in the presence of
comorbidities such as diabetes or hypercholesterolaemia,
or in the presence of co-medications, or wanes with age
[19] is still controversial [56, 192]. In addition, whether the
efficacy of IPost is masked when other forms of cardio-
protection are used, such as IPC, P2Y12 inhibitors, or
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hypothermia and cardioplegia in cardiac surgery, is still
unresolved.
Studies should continue to unravel the numerous and
interacting mechanisms involved in IPost, and how they
relate to other types of conditioning (preconditioning,
perconditioning). In addition to clarifying the mechanisms
of IPost, these studies may lead to the development of
broad spectrum drugs with multiple therapeutic targets
emulating IPost’s broad spectrum therapeutic profile.
Potential loss of cardioprotection in comorbid circum-
stances should be further investigated in large animal
models with genetic predispositions to the comorbidity
spectrum, such as the Ossabaw pig with genetic metabolic
syndrome. Similar studies need to define whether efficacy
of IPost is lost with advancing age. Studies in large animal
models should re-examine the ‘‘ischaemic wavefront’’ to
separate the temporal progression of myocardial injury
after ischaemia only (without reperfusion) and after
ischaemia plus reperfusion to redefine the extent of injury
in patients arriving at the catheter laboratory with unre-
solved occlusions. More clinical studies need to be per-
formed that embrace the design features of randomisation
and adequate statistical power that avoids Type II errors,
and allows stratification of patients into various subgroups
to differentiate responders from non-responders. A com-
bination of different protective interventions, including
remote, per- and postconditioning as well as cocktails of
drugs may be tested in the future.
Myocardial reperfusion injury
Reperfusion Injury has many facets. Apart from reversible
forms of reperfusion injury, including reperfusion arrhyth-
mias and stunning, there is also lethal reperfusion injury, or
cell death, occurring at the time of reperfusion, and thus
preventable by treatments applied at the time of restoration
of blood flow [196]. There is extremely solid evidence of the
existence of lethal reperfusion injury in experimental MI
models. There is also solid evidence of the occurrence of
reperfusion injury in patients with STEMI, although several
interventions to reduce lethal reperfusion injury in patients
have failed or provided inconsistent results in this clinical
setting [76, 106, 110]. The reasons for these failures aremore
likely dependent on the particular treatments applied or on
associated circumstances (age, comorbidities, treatment
received) than to inter-species differences. Over the past
30 years, the importance and mechanisms of cardiomyocyte
cell death in myocardial reperfusion injury have been elu-
cidated in part. AlteredCa2? handling and PTP opening have
been identified to be complementary pathways of reperfu-
sion-induced cell death, but important questions remain
unsolved [118].
Cardiomyocyte death is the main cause of heart failure,
arrhythmias and death in patients with STEMI, and
depends largely on phenomena occurring within car-
diomyocytes themselves, as shown by the fact that it can be
recapitulated in isolated cardiomyocytes submitted to
transient ischaemia [118], but other cells can contribute, in
particular, platelets [8, 9, 174]. Endothelial cells, in which
metabolism is largely independent of mitochondrial respi-
ration [163] are more tolerant of ischaemia than
cardiomyocytes.
A substantial component of reperfusion-induced cell
death occurs during the initial minutes of reperfusion [91].
Apoptosis plays little, if any, role in reperfusion-induced
cardiomyocyte cell death [168] and selective lack of
expression of executioner caspases 3 or 7, does not modify
MI size or post-MI remodeling in mice [122]. Severe
ischaemia stops mitochondrial respiration, progressively
dissipates mitochondrial membrane potential, and ATP
concentration reaches very low levels and triggers rigor
contracture [188]. ATP hydrolysis secondary to reversal of
respiratory Complex V (ATP synthase) plays an important
role [59]. The inactivity of the Na? ATPase pump leads to
Na? and Ca2? overload through reverse Na?/Ca2?
exchange [196]. Anaerobic metabolism in combination
with reduced catabolite washout causes intracellular aci-
dosis, reaching pH 6.4 within a few minutes. Reperfusion
results in the rapid restoration of energy availability [59]
and intracellular pH [126], and generation of large amounts
of reactive oxygen species (ROS) and additional Ca2?
influx [64].
Altered Ca2? handling is a key factor in reperfusion
injury-cardiomyocyte cell death. Na? concentration may
increase in reperfused cardiomyocytes due to Na? influx
associated with pH normalization and passage of Na? from
adjacent cells via gap junctions favoured by impaired Na?
pump function [213], and Na? influx favours Ca2? influx
through the Na?/Ca2? exchanger [164]. Increased Ca2?
and pH normalisation causes calpain activation [124]
resulting in damage of the subsarcolemmal cytoskeleton
leading to Na? pump dysfunction. Restoration of ATP
availability during initial reperfusion leads to Ca2? uptake
into the sarcoplasmic reticulum (SR) followed, when Ca2?
capacity is exceeded, by Ca2? release through the Ryan-
odine receptor channel (RyR2) resulting in oscillations of
Ca2? concentration that propagates across the cell
favouring arrhythmias, hypercontracture and mitochondrial
Ca2? overload [210]. Hypercontracture can cause cell
death, and transient contractile inhibition during the initial
minutes of reperfusion prevents cardiomyocyte death in
isolated cardiomyocytes, isolated hearts and intact large
animals [66, 222]. Reperfusion-generated ROS cause nitric
oxide synthase (NOS) oxidation and reduced NO-cGMP-
PKG signaling. PKG modulates phospholamban (PLB)
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phosphorylation, SR Ca2? uptake, and Ca2? oscillations,
and treatments normalizing PKG signaling in reperfused
myocardium limit MI size in a number of pre-clinical and
clinical studies [123].
Resumption of respiration is associated with increased
ROS generation, due in part to re-oxidation of succinate
accumulated during ischaemia and reverse electron transport
between complex II and complex I of the respiratory chain
[36] and to restoration of mitochondrial potential favoring
mitochondrial Ca2? uptake through the Ca2? uniporter and
Ca2? overload [64]. Studies in mitochondrial preparations
and cells show thatmitochondrial Ca2? andROSmay trigger
an abrupt increase in the permeability of the inner mito-
chondrial membrane resulting in release of molecules from
the mitochondrial matrix into the cytosol, mitochondrial
depolarisation and swelling [85, 185, 186]. Mitochondrial
permeability transition is supposed to be due to the opening
of the PTP, a proposed large conductance cannel in the inner
mitochondrial whose molecular structure is not really clear
[103], except for the involvement of cyclophilin D and more
recently ATP synthase. PTP opening is inhibited by low pH
and favored by ROS and low ATP concentration, conditions
occurring during myocardial reperfusion [72].
Mitochondrial permeability transition and Ca2? oscil-
lations/hypercontracture are closely related cell death
pathways. This is partly due to the tight physical connec-
tion between SR and mitochondria allowing preferential
Ca2? exchange between both organelles [212]. Ca2?
release from mitochondria secondary to PTP opening may
cause hypercontracture in Ca2? overloaded cardiomy-
ocytes [211] while SR-driven Ca2? oscillations may cause
PTP opening [210]. The relative importance of these two
pathways may depend on conditions such as the severity of
the ischaemic insult [214].
Opening of the PTP has been well documented in
mitochondrial preparations exposed to very high Ca2?
concentrations and isolated cardiomyocytes subjected to
simulated IRI [72]. The most important evidence for the
role of PTP in reperfusion injury is the reduced MI size
associated with genetic ablation of cyclophilin D
[6, 75, 81, 183]. Inhibition of cyclophilin D with cyclos-
porine-A (CsA) prevents PTP opening in mitochondrial
preparations but reductions in MI size with this agent have
not been consistent, particularly when applied exclusively
at the time of reperfusion or in large animals [130, 228],
and a positive proof-of-concept trial in patients with
STEMI [195] was not confirmed in a larger phase III trial
[43]. Furthermore, all other drugs aimed at PTP inhibition
in STEMI patients have so far failed. Although disap-
pointing, these results are more likely explained by inef-
fective PTP inhibition by CsA, rather than the PTP not
being important in human reperfusion injury.
Reperfusion signalling via the RISK and SAFE
pathway
It is now well established that ischaemic conditioning
protects the heart from acute IRI through the activation of
signal transduction pathways recruited at the onset of
reperfusion. These signalling cascades mediate the car-
dioprotective signal elicited by ischaemic conditioning
from the sarcolemma to the mitochondria and include,
amongst others, the reperfusion injury salvage kinase
(RISK), and the survivor activating factor enhancement
(SAFE) pathways (reviewed in [80, 92, 94, 145, 146]).
The RISK pathway refers to the pro-survival kinases,
Akt and Erk1/2, the activation of which at the onset of
reperfusion reduces MI size [92, 94]. It was first described
by Yellon and colleagues in 2002 while studying the sig-
nalling mechanisms underlying the cardioprotective effect
induced by the growth factor, urocortin [218]. In that study
the administration of urocortin specifically at the time of
myocardial reperfusion reduced MI size and increased the
phosphorylation of myocardial Erk1/2, the effects of which
were abrogated by the co-administration of the pharma-
cological MEK1/2-Erk1/2 inhibitor, PD98059, at the time
of reperfusion [218]. A large number of experimental
studies have linked the activation of the RISK pathway to
the cardioprotection induced by a diverse variety of phar-
macological agents including growth factors, cytokines,
and other agents such as metformin and statins [92, 94].
The RISK pathway has also been shown to mediate the
cardioprotection induced by IPC and IPost, suggesting that
it may be a common pathway for cardioprotection
[86, 87, 245]. Most of the experimental studies implicating
the RISK pathway as a cardioprotective pathway have been
performed in small rodent models of AMI, whereas recent
studies suggest that the RISK pathway does not appear to
mediate the cardioprotection induced by IPost [132, 229],
gentle reperfusion [182] or RIC [1, 227] in large animal
models, suggesting species differences in the reperfusion
signalling pathways underlying ischaemic conditioning.
In 2005, Lecour and colleagues made the unexpected
observation that the MI-limiting effects of TNF-a at the
onset of reperfusion were mediated independently of the
RISK pathway [147, 148]. They subsequently discovered,
that TNF-a administered at the onset of myocardial
reperfusion recruited an alternative signalling cascade,
termed the SAFE pathway [142, 145, 146, 148], by binding
to TNF receptor type 2 and activating Janus Kinase (JAK)
and Signal transducer and activator of transcription 3
(STAT3) via mechanisms which are still unclear but may
involve sphingosine kinase [61]. A number of experimental
studies have demonstrated that pharmacological condi-
tioning mimetics which limit myocardial reperfusion injury
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do so via the activation of the SAFE pathway, including
high density lipoproteins [62], melatonin [144], glyceryl-
trinitrate, and cariporide [140]. In IPC studies, the activa-
tion of the SAFE pathway was demonstrated to occur at
two time-points, following the IPC protocol and at the
onset of reperfusion [148, 236]. The activation of the SAFE
pathway by ischaemic conditioning has been confirmed
both in small and large animals of AMI [227], whereas in
humans, the STAT-5 isoform appears to be preferentially
activated [109].
It has been demonstrated that there exists crosstalk
between the Akt and Erk1/2 components of the RISK
pathway such that the pharmacological inhibition of one
kinase activated the other kinase to ensure maximal pro-
tection against myocardial reperfusion injury [83]. Inter-
estingly, a crosstalk also exists between the RISK and the
SAFE pathways [232]. Both signaling pathways converge
on mitochondria where they appear to mediate their car-
dioprotective effect by inhibiting PTP opening [16, 46].
The mechanism for this is unclear for the RISK pathway,
but for the SAFE pathway, STAT-3 has been shown to be
present in mitochondria, where it modulates mitochondrial
respiration and targets the PTP [16, 108]. TNF-a itself can
also directly target mitochondrial function [141].
Whether targeting the RISK and SAFE pathway can
benefit patients subjected to acute myocardial IRI has not
been directly tested, although pharmacological agents such
as atrial natriuretic peptide, erythropoietin and statins,
which are known to activate components of these two
signaling cascades, have been investigated in the clinical
setting with mixed results [160, 161]. Further studies are
required to test whether using combination therapy to
simultaneous target the RISK, SAFE and other pathways is
a more effective cardioprotective strategy than focusing on
one single signaling cascade.
Mitochondria as targets of cardioprotection
The apparent paradox of IPC, whereby a short period of
ischaemia protects from an otherwise lethal ischaemic
episode, is reflected and likely contributed to, by para-
doxical actions of Ca2? and ROS in mitochondria.
Undoubtedly, a large and prolonged elevation in Ca2? and
ROS levels causes cell death mainly by favoring PTP
opening [13]. However, antioxidants abolish IPC protec-
tion [189], that is mimicked by a mild elevation in ROS or
Ca2? levels [264, 266]. Several processes have been pro-
posed to explain the paradoxical involvement of ROS and
Ca2? in both survival and death of cardiomyocytes. First,
intra-mitochondrial Ca2? is necessary to stimulate oxida-
tive phosphorylation by activating key dehydrogenase
steps, while sub-lethal levels of ROS activate signaling
pathways promoting cell survival [128]. A mild ROS for-
mation has been proposed also to explain the protection
related to the opening of mitochondrial KATP channels
downstream of PKC-e activation and upstream of PTP
inhibition [41].
Besides the elucidation of the molecular nature of PTP,
KATP channels and other potential targets of IPC protec-
tion, a major challenge in the field is to determine the
threshold separating physiological from pathological levels
of ROS and Ca2?. This issue can be addressed by
exploiting technological advances in Ca2? and ROS
imaging that have largely contributed to our understanding
of IRI and IPC protection. Early studies by Michael Piper
using the Ca2?-sensitive, fluorescent dye Fura-2 demon-
strated that the recovery of ATP production in isolated
cardiomyocytes with Ca2? overload during reoxygenation
leads to Ca2? oscillations and hypercontracture [223]. It
was proposed that Ca2? microdomains in the vicinity of the
SR could raise local [Ca2?] to levels sufficient to drive
mitochondrial Ca2? entry. Subsequent experiments using
the mitochondria-targeted, Ca2?-sensitive photoprotein,
aequorin, helped to validate the concept of these Ca2? ‘‘hot
spots’’. Importantly, mitochondrial Ca2? uptake contributes
to the buffering of cytoplasmic Ca2? peaks in cardiomy-
ocytes [53]. However, during reperfusion massive cytosolic
Ca2? oscillations can lead to mitochondrial Ca2? overload
and PTP opening [64]. Oxidative stress during reperfusion
can accentuate SR Ca2? release [45]. These cytosolic and
mitochondrial Ca2? changes also occur in perfused hearts
during IRI, as was initially demonstrated by imaging Ca2?
using fluorescent dyes and microscopy [248], and more
recently with genetically encoded reporters and multipho-
ton microscopy [48]. IPC was shown to attenuate ischae-
mic SR Ca2? overload in the isolated rabbit heart [34].
The elucidation of signalling pathways related to IPC-
induced protection commenced with the seminal discovery
of the involvement of the adenosine receptor in IPC [153].
Several of the described pathways converge on cytosolic
Akt and/or ERK, which lead to the activation of mito-
chondrial PKC-e [177]. Activated mitochondrial PKC-e
induces not only opening of the mKATP channel but also
activation of Akt-GSK3b signalling in mitochondria, both
of which contribute to inhibition of PTP opening [176].
Despite the redundancy of IPC-induced signal pathways in
the cytosol and mitochondria, several diseases have been
shown to significantly impair IPC-induced signalling in the
myocardium. Interestingly, diabetes mellitus attenuates
activation of Akt in response to upstream signals
[116, 173, 244, 245] and also lowers the threshold for PTP
opening by enhanced mitochondrial recruitment of non-
phosphorylated GSK3b [172, 237] and increased ER stress
[127]. Recently, progress has been made in our under-
standing of PTP and mitochondrial Ca2? uniporter.
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However, the intra-mitochondrial localisation of protein
kinases and phosphatases and their relationships with PTP,
ROS and Ca2? regulating machineries remain unclear and
warrant further investigation.
Beyond its participation in signal transduction during
IPC, mitochondria are effectors of cardioprotection. IPC
attenuates IRI-induced mitochondrial respiratory failure
and oxidative damage independently of PTP opening, even
in the absence of cytosolic components [178]. Importantly,
Cx43 translocates to and is predominantly present at sub-
sarcolemmal mitochondria [20] and subsarcolemmal
mitochondria but not interfibrillar mitochondria are the
main targets of IRI damage and IPC protection [20, 206].
Indeed, mitochondria with genetic ablation of Cx43 are
resistant to preconditioning [20, 206, 212]. Mitochondrial
Cx43 regulates complex 1-mediated respiration [18, 175],
ROS production [98] and K? permeability [175], although
its participation in IRI pathophysiology remains unclear in
detail. The role of subsarcolemmal mitochondria in car-
dioprotection is necessarily linked to the function of
interfibrillar mitochondria, as the latter are involved in
cytosolic calcium buffering, energy demand–supply
matching and antioxidant regeneration through privileged
communication with SR [51, 212]. Indeed, partial disrup-
tion of mitochondria-SR interplay appears to aggravate
IRI-induced cytosolic calcium, hypercontracture, PTP
opening and cell death in aged mice [59, 60]. Variations in
mitochondrial Cx43 contents might explain the resistance
against IPC-mediated cardioprotection observed in aged
animals [17, 19, 219].
Pharmacological targeting of myocardial IRI
Elucidation of the signaling pathways underlying ischae-
mic conditioning cardioprotection has identified a large
variety of therapeutic targets for pharmacological cardio-
protection. In this section, we review some of the more
recent pharmacological therapies which have been inves-
tigated in the clinical setting to target myocardial IRI in
reperfused STEMI patients.
GLP-1
Glucagon-like peptide-1 (GLP-1) is an incretin hormone
that regulates plasma glucose, and within the latest
10 years GLP-1 analogues have been introduced for
treatment of type-2 diabetes [89, 112]. In addition, recep-
tors for GLP-1 have been found in the heart [7]. In
experimental studies GLP-1 or its analogues protect against
reperfusion injury-induced cell death [23, 24, 88, 89, 243].
These cardioprotective analogues include exendin-4, a
peptide derived from the saliva of the Gila lizard showing a
GLP-1-like potency and efficacy at GLP-1 receptors
[95, 255]. Exendin-4 was found to be cardioprotective
during reperfusion in isolated rat hearts [233], a finding that
has been confirmed in several species, e.g. pigs [242].
Intravenous (IV) exenatide was found to increase
myocardial salvage by 15 % if administered as a 6 h
infusion initiated 10 min before reperfusion in STEMI
patients [157]. When examining only patients with short
ischaemic times (\132 min) MI size was reduced by 30 %
[156]. This effect of exenatide was confirmed in an Asian
population, since Woo et al. observed an almost 50 %
reduction in MI size when administered subcutaneously
[263]. A recent clinical study has failed to demonstrate a
cardioprotective effect with exenatide in STEMI patients—
it is not clear why this study was neutral, but it may have
been related to the dose used [208]. To date no trials have
sought to challenge the results from the proof-of-concept
studies on a clinical end point.
Cyclosporin-A
Opening of the PTP is a critical signalling hub in the
cascade of myocardial reperfusion injury and preventing it
from opening has been suggested to be an obvious phar-
macological target [82, 85, 185, 186]. CsA is a compound
that preserves PTP closure and in addition, it has been
reported to affect remodelling following MI [170].
In a small proof-of-concept study Piot et al. demonstrated
that CsA can reduce enzyme leakage by 40 % andMI size by
20 % when administered as an IV bolus prior to PPCI
[96, 195]. Both infarcts located in RCA and LAD were
included but only patients with TIMI 0 were eligible. The
more recent CYCLE trial recruited 410 STEMI patients
within 6 h of symptom onset (TIMI flow grade 0–1) and
randomized them to CsA (2.5 mg/kg) or control [187]. The
primary endpoint (ST-segment resolution at 60 min) and
secondary endpoints (high-sensitivity cardiac troponin T
(hs-cTnT) on day 4, left ventricular (LV) remodelling, and
clinical events at 6-months follow-up) were not reduced by
CsA [187]. Finally, in the definite hard endpoints-powered
CIRCUS trial, 970 anterior STEMI patients (TIMI flow 0–1
in the LAD) were randomised to CsA or placebo. The trial
failed to show any effect of IV CsA on a composite endpoint
of death, hospitalization for heart failure and adverse LV
remodelling [195]. The reasons for CsA to improve clinical
outcomes in STEMI patients are not known and have been
discussed in several recent articles [76, 100].
Metoprolol
Early beta-blocker therapy in reperfused STEMI patients is
controversial and had largely been investigated in the pre-
reperfusion era. However, recently it has been shown that
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IV metoprolol administered prior to reperfusion in a por-
cine model reduced MI size [120]. This experimental work
was followed by a clinical trial (METOCARD-CNIC trial)
demonstrating that IV metoprolol administered in the
ambulance prior to PPCI reduced MI size and improved
clinical outcomes (as a secondary endpoint) in anterior
STEMI patients presenting early (\6 h) [119, 197]. More
importantly, in the METOCARD-CNIC trial, patients
receiving pre-reperfusion IV metoprolol had not only
CMR-evaluated smaller infarctions [166], and better long-
term left ventricular ejection fraction (LVEF) [197], but
also the incidence of LV severe systolic dysfunction was
significantly reduced [197]. Very recently, the results of the
EARLY BAMI trial have been reported. This trial recruited
600 STEMI patients (any location) presenting within 12 h
from symptoms onset. Patients were randomized to IV
metoprolol (10 mg) or placebo [207]. Primary endpoint
was MI size assessed by CMR one month after infarction.
The trial was neutral and MI size was not smaller in
patients allocated to IV metoprolol. There were no signs of
adverse effects in patients receiving IV metoprolol, and the
incidence of ventricular fibrillation was significantly lower
in metoprolol-treated patients. These data support the
safety of this strategy in Killip I–II STEMI patients. There
are important differences between the METOCARD-CNIC
and EARLY BAMI trials. Dose and timing of IV meto-
prolol administration were different between trials. In
contrast to the METOCARD-CNIC trial, in the EARLY
BAMI study, patients received only one 5 mg dose at
recruitment, and per protocol the second dose was given in
the catheter laboratory immediately before PCI. In fact, the
first dose of metoprolol did not have any effect on blood
pressure or heart rate, suggesting an underdosing effect. In
this regard, a recent subanalysis from the METOCARD-
CNIC trial demonstrated that the longer the ‘‘onboard’’
metoprolol time at the time of reperfusion, the higher the
infarct-reduction effect [67]. In fact, patients receiving IV
metoprolol close to reperfusion had a very mild protective
effect, while those with a longer time from metoprolol
15 mg bolus to reperfusion were those with the largest
reduction in MI size and improvement in long-term LVEF.
These differences in dose and timing of metoprolol
administration might explain the different conclusions
from both trials. Given the clear safety profile and the low
cost of this therapy, it is worth to continue the clinical
research and perform a definite large hard endpoint-pow-
ered trial. In the near future, the MOVE ON! Trial will be
initiated and more than 1200 anterior STEMI patients will
be recruited and randomized to IV metoprolol (15 mg
immediately after diagnosis is made in the out of hospital
setting) or placebo. The primary endpoint will be the
composite of cardiovascular death, heart failure, ICD
insertion, or severe LV dysfunction.
P2Y12 inhibitors
State of the art anti-thrombotic therapy in STEMI patients
includes the early administration of P2Y12 inhibitors.
Ticagrelor, a potent P2Y12 inhibitor was associated with
reduced mortality in ACS patients when compared to
another P2Y12 inhibitor (clopidogrel) [253]. These benefits
may not be fully explained by a pure antiplatelet effect. In
this regard, ticagrelor has been shown, to increase the
levels of extracellular adenosine [21], a mediator known to
exert a wide range of benefits including vasodilation,
inhibition of platelet aggregation and leukocyte adherence
to the vessel wall. In line with this, cangrelor, a potent and
fast acting IV P2Y12 inhibitor, has been shown to reduce
MI size in mouse [12], rat [267], rabbit [268], and primates
[269]. Interestingly, the protection conferred by cangrelor
is dependent upon the presence of platelets with no evi-
dence of protection ex vivo in crystalloid-perfused Lan-
gendorff heart [267, 268]. This protection is mediated
through pathways typically recruited by ischaemic condi-
tioning, suggesting that P2Y12 inhibition, via a blood
component, leads to conditioning-like protection
[267, 268]. Therefore, IV P2Y12 inhibition may thus have
the dual advantage of optimising both platelet inhibition
and offering cardioprotection.
Combination reperfusion therapy—a novel
therapeutic strategy
As can be seen above, most attempts to reduce MI size in
STEMI patients have relied on using a single agent to
target one single component of myocardial IRI. However,
myocardial IRI is the result of several mechanisms and thus
targeting on individual phenomena will unlikely reduce the
MI size. The possibility of targeting several mechanisms
simultaneously (either with one agent targeting different
pathways or by several agents administered simultane-
ously) is attractive although not widely undertaken. A
recent large animal study [1] showed that the combination
of RIC with glucose-insulin-potassium and exenatide had
an additive benefit in terms of MI size reduction. The
COMBAT-MI trial (NCT02404376) will test the potential
benefits of using RIC with exenatide on MI size reduction
in STEMI patient.
Problems in translation to the clinic
and confounding factors
Although much effort has been taken to translate cardio-
protection into clinical practice, so far translation has not
been successful, as still no drugs are on the market and no
therapeutic interventions are available for routine clinical
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practice that may protect the heart after IRI and thereby
prevent the development of post-ischaemic heart failure
[11, 28, 76, 99, 106, 107, 110, 118]. There are two major
problems of clinical translation to overcome in the future:
(1) target discovery and validation taking into considera-
tion the known confounding factors of cardioprotection;
and (2) better design of clinical development studies.
The putative mechanisms of cardioprotection explored
in the past three decades have so far led to potential drug
targets that were not robust enough for their pharmaco-
logical use as clinical trials targeting them largely showed
no efficacy. Although it has been known from preclinical
studies already in the mid-1990s that major cardiovascular
co-morbidities and risk factors including aging, hyperlipi-
demia, diabetes (see for the first extensive review from
1998 on the effect of risk factors on cardioprotection [58],
as well as some later specific reviews on aging [19],
hyperlipidaemia [55], and diabetes [178, 261]) and also
their medications (see for the first extensive review: [57]
and its updated version: [56]) largely modify the response
of the ischaemic heart to cardioprotective therapies, target
discovery and validation were performed and still continue
to be performed in young and healthy animals in the vast
majority of studies. In the future, at least the major known
co-morbidities and their major classes of pharmacological
treatments should be used to validate the potential drug
target before entering into clinical trials. The second reason
may be a simplified and biased way of target selection so
far. It is already known from transcriptomics data from the
early 2000 years that IRI and cardioprotection trigger
multifactorial mechanisms, moreover, co-morbidities and
co-medications also significantly modify the cardiac gene
expression profile (see for extensive reviews: [249]).
Therefore, targeting a single pathway to protect all IHD
patients is obviously not an approach that may lead to
success. In the future, maybe a multi-omics approach
including transcriptomics, proteomics, and metabolomics
followed by systems biological network analysis may
provide novel targets using this unbiased global approach
(see for extensive reviews: [249]).
Although clinical trials of RIC may show some patient
benefit in acute MI patients with multiple co-morbidities
[104], two recent large clinical studies in patients under-
going cardiovascular surgery (ERICCA, RIPHeart)
[77, 171] revealed no evidence for protection. It must be
mentioned, however, that in both of these trials propofol
was used for anesthesia, although propofol has been shown
before to interfere with the efficacy of conditioning
[105, 106]. Some larger clinical studies of IPost so far
showed no acute cardioprotection [70, 134] nor long-term
benefit up to 1 year follow up [71]. Nevertheless, the
results of these clinical studies showed that both RIC and
IPost have a favorable safety profile [110], so further
studies are encouraged using better design and enough
power to find out the importance of confounding factors of
ischaemic conditioning in clinical reality.
As to the clinical development of cardioprotective
drugs, the results so far have been disappointing. Targeting
mitochondria by PTP inhibitors and other mitochondrial
protective compounds (CIRCUS, CYCLE, Bendavia,
Mitocare, EMBRACE STEMI studies) or replacing NO by
inhaled NO (NOMI trial) or nitrite administration were
ineffective in clinical trials (see for a recent review [76]). It
should be noted that the molecular targets of these drugs
were not validated properly before entering into clinical
trials, i.e. targets were selected by the traditional biased
way and no validations have been attempted in any of the
animal models with the presence of the confounding fac-
tors. In the future, based on careful preclinical validation,
phase 2 studies with careful patient selection based on the
relevant confounding factors for the specific molecular
target(s) may open new perspectives for successful trans-
lation of cardioprotection. Also, given the complexity of
the cardioprotective signal transduction [101], combined
treatment of several targets maybe needed.
Conclusions
In this article we have provided an overview of the major
topics discussed at this special meeting to celebrate
30 years of research in the field of IPC and cardioprotec-
tion. The huge research literature, which has arisen from
the seminal discovery of IPC, has provided important
insights into the mechanisms and elucidation of the sig-
nalling pathways underlying cytoprotection in the heart and
other organs. The evolution of IPC to both IPost and RIC
has helped facilitate the translation of this endogenous
cardioprotective strategy from the laboratory to the clinical
setting. We hope this article provides a worthy account of
the huge importance and impact the discovery of IPC has
made in the field of cardiovascular research over the last
30 years.
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